Nirmatrelvir-d6

Nirmatrelvir-d6 (PF-07321332-d6) is deuterium labeled Nirmatrelvir. Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research[1].

Product Specifications

CAS Number

[2861202-75-5]

Product Name Alternative

PF-07321332-d6

UNSPSC

12352005

Target

Isotope-Labeled Compounds; SARS-CoV

Related Pathways

Anti-infection; Others

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Smiles

O=C(NCC1)[C@@H]1C[C@@H](C#N)NC([C@@H]2[C@]3([H])[C@@](CN2C([C@H](C(C)(C)C)NC(C(F)(F)F)=O)=O)([H])C3(C([2H])([2H])[2H])C([2H])([2H])[2H])=O

Molecular Formula

C23H26D6F3N5O4

Molecular Weight

505.56

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]KoenVandyck, et al. Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection. Current Opinion in Virology Available online 27 April 2021